Radiation dermatitis: current view on pathogenesis, principles of profilaxis and treatment
T. S. Belysheva,
T. T. Valiev,
E. A. Shatokhina,
V. A. Grigorenko,
A. S. Polonskaya,
K. I. Kirgizov,
S. R. Varfolomeeva https://doi.org/10.21682/2311-1267-2022-9-4-81-87
Abstract
Radiation therapy (RT) is associated with high incidence of dermatologic adverse events. Radiation dermatitis is a major cutaneous side effect of RT. The article presents current views on pathogenesis of radiation dermatitis and modern approaches to prophylaxis and treatment of this cutaneous reaction.
Supporting agencies: The study was performed without external funding
About the Authors
T. S. Belysheva
N. N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Leading Researcher
Research Institute of Pediatric Oncology and Hematology
Scientific Advisory Division
115478
23 Kashirskoe Shosse
Moscow
T. T. Valiev
N. N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Head of the Department
Research Institute of Pediatric Oncology and Hematology
Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) No. 1
115478
23 Kashirskoe Shosse
Moscow
E. A. Shatokhina
Central State Medical Academy Department for Presidential Affairs of the Russian Federation; Medical Research and Educational Center at the Lomonosov Moscow State University
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor of Department, Senior Fellow
Dermatovenerology and Cosmetology Department
121359
Bld. 1A, 19 Marshala Timoshenko St.
Internal Medicine Department
119991
Bld. 10, 27 Lomonosovsky Prosp.
Moscow
V. A. Grigorenko
N. N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Radiotherapist, Head of the Department
Research Institute of Pediatric Oncology and Hematology
Radiological Department
115478
23 Kashirskoe Shosse
Moscow
A. S. Polonskaya
Central State Medical Academy Department for Presidential Affairs of the Russian Federation
Russian Federation
Russian Federation
Assistant
Dermatovenerology and Cosmetology Department
121359
Bld. 1A, 19 Marshala Timoshenko St.
Moscow
K. I. Kirgizov
N. N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Deputy Director for Scientific and Educational Work
Research Institute of Pediatric Oncology and Hematology
115478
23 Kashirskoe Shosse
Moscow
S. R. Varfolomeeva
N. N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor, Director
Research Institute of Pediatric Oncology and Hematology
115478
23 Kashirskoe Shosse
Moscow
References
1. Lacouture M. E. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients. John Wiley & Sons, 2014.
2. Salvo N., Barnes E., van Draanen J., Stacey E., Mitera G., Breen D., Giotis A., Czarnota G., Pang J., De Angelis C. Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature. Curr Oncol. 2010; 17 (4): 94–112. doi: 10.3747/co.v17i4.493.
3. Janko M., Ontiveros F., Fitzgerald T. J., Deng A., DeCicco M., Rock K. L. IL-1 generated subsequent to radiation-induced tissue injury contributes to the pathogenesis of radiodermatitis. Radiat Res. 2012; 178 (3): 166–72. doi: 10.1667/rr3097.1.
4. Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol. 2011; 11 (3): 213–20. doi: 10.1038/nri2936.
5. Allam R., Lawlor K. E., Yu E. C. Mitochondrial apoptosis is dispensable for NLRP3 infl ammasome activation but non-apoptotic caspase-8 is required for infl ammasome priming. EMBO Rep. 2014; 15 (9): 982–90. doi: 10.15252/embr.201438463.
6. Pohlers D., Brenmoehl J., Löffler I. TGF-beta and fibrosis in diff erent organs – molecular pathway imprints. Biochim Biophys Acta. 2009; 1792 (8): 746–56. doi: 10.1016/j.bbadis.2009.06.004.
7. Flanders K. C. Smad 3 as a mediator of the fi brotic response. Int J Exp Pathol. 2004; 85 (2): 47–64. doi: 10.1111/j.0959-9673.2004.00377.x.
8. Martin D. J., Garske J. P., Davis M. K. Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. J Consult Clin Psychol. 2000; 68 (3): 438–50. PMID: 10883561.
9. Vorotnikova E., Rosenthal R. A., Tries M., Doctrow S. R., Braunhut S. J. Novel synthetic SOD / catalase mimetics can mitigate capillary endothelial cell apoptosis caused by ionizing radiation. Radiat Res. 2010; 173 (6): 748–59. doi: 10.1667/RR1948.1.
10. Dent P., Yacoub A., Fisher P. B., Hagan M. P., Grant S. MAPK pathways in radiation responses. Oncogene. 2003; 22 (37): 5885–96. doi: 10.1038/sj.onc.1206701.
11. Drummond G. R., Selemidis S., Griendling K. K., Sobey C. G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011; 10 (6): 453–71. doi: 10.1038/nrd3403.
12. Panday A., Sahoo M. K., Osorio D., Batra S. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell Mol Immunol. 2015; 12 (1): 5–23. doi: 10.1038/cmi.2014.89.
13. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004; 75 (6): 639–53. doi: 10.1016/j.lfs.2003.10.042.
14. Ohta S., Matsuda S., Gunji M., Kamogawa A. The role of nitric oxide in radiation damage. Biol Pharm Bull. 2007; 30 (6): 1102–7. doi: 10.1248/bpb.30.1102.
15. Frey B., Rückert M., Deloch L. Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of infl ammatory diseases. Immunol Rev. 2017; 280 (1): 231–48. doi: 10.1111/imr.12572.
16. Yahyapour R., Amini P., Rezapoor S. Targeting of Infl ammation for Radiation Protection and Mitigation. Curr Mol Pharmacol. 2018; 11 (3): 203–10. doi: 10.2174/1874467210666171108165641.
17. Gorski D. H., Beckett M. A., Jaskowiak N. T. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59 (14): 3374–8. PMID: 10416597.
18. Tong R. T., Boucher Y., Kozin S. V., Winkler F., Hicklin D. J., Jain R. K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004; 64 (11): 3731–6. doi: 10.1158/0008-5472.CAN-04-0074.
19. Wendt T. G., Grabenbauer G. G., Rödel C. M. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998; 16 (4): 1318–24. doi: 10.1200/JCO.1998.16.4.1318.
20. Swift M., Morrell D., Cromartie E., Chamberlin A. R., Skolnick M. H., Bishop D. T. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet. 1986; 39 (5): 573–83. PMID: 3788973.
21. Iannuzzi C. M., Atencio D. P., Green S., Stock R. G., Rosenstein B. S. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys. 2002; 52 (3): 606–13. doi: 10.1016/s0360-3016(01)02684-0.
22. Meghrajani C. F., Co H. C., Ang-Tiu C. M., Roa F. C. Topical corticosteroid therapy for the prevention of acute radiation dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol. 2013; 6 (6): 641–9. doi: 10.1586/17512433.2013.841079.
23. McQuestion M. Evidence-based skin care management in radiation therapy. Semin Oncol Nurs. 2006; 22 (3): 163–73. doi: 10.1016/j.soncn.2006.04.004.
24. Frederick D. M., Renato G. P. Radiobiology and radiation effects. In: Wolff K., Goldsmith L. A., Katz S. I., Gilchrest B. A., Paller A. S., Leffell D. J., eds. Fitzpatrick’s dermatology in general medicine. 7<sup>th</sup> ed. New York: McGraw-Hill, 2008. Pp. 858–862.
25. Bray F. N., Simmons B. J., Wolfson A. H., Nouri K. Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy. Dermatol Ther (Heidelb). 2016; 6 (2): 185–206. doi: 10.1007/s13555-016-0120-y.
26. Bernier J., Domenge C., Ozsahin M. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350 (19): 1945–52. doi: 10.1056/NEJMoa032641.
27. Madison K. C. Barrier function of the skin: “la raison d'être” of the epidermis. J Invest Dermatol. 2003; 121 (2): 231–41. doi: 10.1046/j.1523-1747.2003.12359.x.
28. Porock D., Kristjanson L., Nikoletti S., Cameron F., Pedler P. Predicting the severity of radiation skin reactions in women with breast cancer. Oncol Nurs Forum. 1998; 25 (6): 1019–29. PMID: 9679261.
29. Cox J. D., Stetz J., Pajak T. F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31 (5): 1341–6. doi: 10.1016/0360-3016(95)00060-C.
30. Chan R. J., Webster J., Chung B., Marquart L., Ahmed M., Garantziotis S. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2014; 14: 53. doi:10.1186/1471-2407-14-53.
31. Bolderston A., Lloyd N. S., Wong R. K., Holden L., Robb-Blenderman L.; Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-Based Care. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer. 2006; 14 (8): 802–17. doi: 10.1007/s00520-006-0063-4.
32. Wong R. K., Bensadoun R. J., Boers-Doets C. B. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2013; 21 (10): 2933–48. doi: 10.1007/s00520-013-1896-2.
33. Ponomarenko G. N. General Physiotherapy: textbook. 5<sup>th</sup> ed., revised. and additional. M.: GEOTAR-Media, 2013. 365 p. (In Russ.)
34. Elad S., Cheng K. K. F., Lalla R. V. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy [published correction appears in Cancer. 2021; 127 (19): 3700]. Cancer. 2020; 126 (19): 4423–31. doi: 10.1002/cncr.33100.
35. Tran T. N., Hoang M. V., Phan Q. A. Fractional epidermal grafting in combination with laser therapy as a novel approach in treating radiation dermatitis. Semin Cutan Med Surg. 2015; 34 (1): 42–7. doi: 10.12788/j.sder.2015.0141.
36. Saei S., Sahebnasagh A., Ghasemi A. Efficacy of sucralfate ointment in the prevention of acute proctitis in cancer patients: A randomized controlled clinical trial. Caspian J Intern Med. 2020; 11 (4): 410–8. doi: 10.22088/cjim.11.4.410.
37. Kouvaris J. R., Kouloulias V. E., Plataniotis G. A., Kokakis J. D., Vlahos L. J. Topical granulocyte-macrophage colony-stimulating factor for radiation dermatitis of the vulva. Br J Dermatol. 2001; 144 (3): 646–7. doi: 10.1046/j.1365-2133.2001.04115.x.
38. Dunst J., Semlin S., Pigorsch S., Müller A. C., Reese T. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlenther Onkol. 2000; 176 (9): 416–21. doi: 10.1007/pl00002350.
39. Viswanath L., Bindhu J., Krishnamurthy B., Suresh K. P. Granulocyte-Colony Stimulating Factor (G-CSF) accelerates healing of radiation induced moist desquamation of the skin. Klin Onkol. 2012; 25 (3): 199–205. PMID: 22724569.
40. Common terminology criteria for adverse events (CTCAE) version 4.0 (May 28, 2009) [Electronic resource: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf]. US Department of Health and Human Services; National Institute of Health, National Cancer Institute v.4.03. 2010.
Review
For citations:
Belysheva T.S., Valiev T.T., Shatokhina E.A., Grigorenko V.A., Polonskaya A.S., Kirgizov K.I., Varfolomeeva S.R. Radiation dermatitis: current view on pathogenesis, principles of profilaxis and treatment. Russian Journal of Pediatric Hematology and Oncology. 2022;9(4):81-87. (In Russ.) https://doi.org/10.21682/2311-1267-2022-9-4-81-87
Views:
809
Email this article 